Clinical Trial Update: Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cemiplimab added to surgery for advanced eyelid/skin squamous cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eyelid Squamous Cell Carcinoma
• Head and Neck Cutaneous Squamous Cell Carcinoma
• Skin Squamous Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING